Glenmark Lays Out US Flovent Plans, Discusses Growing Debt Pile
Welcomes ‘Strong Uptake’ For Ryaltris In EU, Reveals Further Filing Plans
India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.